Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Asia Life Sciences IPO Landscape: China, Hong Kong March Ahead But Watch India

Executive Summary

Four key Asian markets witnessed nearly 200 life science company listings over the past 10 years, with China dominating the scene and expected to stay ahead, along with Hong Kong, for the foreseeable future. But India could prove a new contender over time as firms move up the value chain, a new report shows.

You may also be interested in...



US Revocation Of Hong Kong Special Status To Rain On Biotech IPO Parade?

Amid a sweeping National Security Law passage, many biotech and healthcare firms from China opt for a Hong Kong initial public offering in the meanwhile appetite for a US listing wanes.

IPO Update: High-Flying Biopharma IPOs Average 77.1% Return Through Q2

The performance of 29 biopharma firms that launched IPOs during the first half of 2020 is staggering compared with 28 drug developers that went public in the first half of 2019 with a 10% average return.

No Love From US: Senate Bill Deals Blow To Aspiring China Biotechs

In a bipartisan move, the US Senate is moving to impose new rules on companies - including those from China - seeking US initial public offerings, adding further uncertainty over such plans and further stoking trade tensions.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1133148

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel